Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Hoelzer, R Bassan, H Dombret… - Annals of …, 2016 - annalsofoncology.org
The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …
Clinical updates in adult acute lymphoblastic leukemia
O Al Ustwani, N Gupta, H Bakhribah, E Griffiths… - Critical Reviews in …, 2016 - Elsevier
Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by B or T lineage.
Here we cover the clinical manifestations, pathophysiology and therapy for ALL …
Here we cover the clinical manifestations, pathophysiology and therapy for ALL …
[HTML][HTML] Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study
M Cheminant, C Derrieux, A Touzart, S Schmit… - …, 2016 - ncbi.nlm.nih.gov
Quantification of minimal residual disease may guide therapeutic strategies in mantle cell
lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard …
lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard …
Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis
N Bleyzac, D Cuzzubbo, C Rénard, N Garnier… - Bone marrow …, 2016 - nature.com
There is currently a major concern regarding the optimal immunosuppression therapy to be
administered after hematopoietic stem cell transplantation (HSCT) to reduce both the toxicity …
administered after hematopoietic stem cell transplantation (HSCT) to reduce both the toxicity …
Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia
HF Li, WT Meng, YQ Jia, NG Jiang, TT Zeng, YM Jin… - Medicine, 2016 - journals.lww.com
B cell acute lymphoblastic leukemia (B-ALL) exhibits phenotypes reminiscent of normal
stages of B-cell development. As demonstrated by flow cytometry, the immunophenotypes …
stages of B-cell development. As demonstrated by flow cytometry, the immunophenotypes …
Key markers of minimal residual disease in childhood acute lymphoblastic leukemia
M Xia, H Zhang, Z Lu, Y Gao, X Liao… - Journal of Pediatric …, 2016 - journals.lww.com
The aim of this study was to identify key markers of minimal residual disease (MRD) in
childhood Acute Lymphoblastic Leukemia (ALL). Bone marrow samples were collected at …
childhood Acute Lymphoblastic Leukemia (ALL). Bone marrow samples were collected at …
Методические основы диагностики и мониторинга минимальной остаточной болезни при острых лейкозах у детей первого года жизни
ГА Цаур, АМ Попов, ЛГ Фечина, СА Румянцев - Онкогематология, 2016 - cyberleninka.ru
В статье представлены методические основы и показана прогностическая ценность
определения минимальной остаточной болезни (МОБ) у детей первого года жизни с …
определения минимальной остаточной болезни (МОБ) у детей первого года жизни с …
Acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of disorders which
originate from various important genetic lesions in B and T progenitor cells, including …
originate from various important genetic lesions in B and T progenitor cells, including …
[HTML][HTML] Methodological aspects of diagnostics and minimal residual disease monitoring in infant acute leukemias
GA Tsaur, AM Popov, LG Fechina… - …, 2016 - oncohematology.abvpress.ru
Hereby we present methodological aspects and prognostic significance of minimal residual
disease (MRD) monitoring in infant acute leukemias. Based on our own experience we …
disease (MRD) monitoring in infant acute leukemias. Based on our own experience we …
[PDF][PDF] Az onkohematológia molekuláris diagnosztikai vizsgálómódszereinek alapjai
KP ATTILA, A DONÁT, F VIKTÓRIA, M DÓRA… - Magyar Onkológia, 2016 - huon.hu
BEVEZETÉS A technológiai fejlődés elmúlt évtizedekben való felgyorsulásának
köszönhetően számos onkohematológiai megbetegedés genetikai hátterét ismertük meg …
köszönhetően számos onkohematológiai megbetegedés genetikai hátterét ismertük meg …